
Thorsten Langer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8021983/publications.pdf Version: 2024-02-01



THOPSTEN LANCER

#	Article	IF	CITATIONS
1	Understanding platinum-induced ototoxicity. Trends in Pharmacological Sciences, 2013, 34, 458-469.	4.0	183
2	Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany. Journal of Neuromuscular Diseases, 2018, 5, 135-143.	1.1	97
3	Discrepancy in redetermination of <i>SMN2</i> copy numbers in children with SMA. Neurology, 2019, 93, 267-269.	1.5	43
4	Patients and families as teachers: a mixed methods assessment of a collaborative learning model for medical error disclosure and prevention. BMJ Quality and Safety, 2016, 25, 615-625.	1.8	31
5	Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1. European Journal of Paediatric Neurology, 2018, 22, 122-127.	0.7	31
6	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	1.3	31
7	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics Journal, 2020, 20, 294-305.	0.9	28
8	A longitudinal, randomized, and prospective study of nocturnal monitoring in children and adolescents with epilepsy: Effects on quality of life and sleep. Epilepsy and Behavior, 2016, 61, 192-198.	0.9	13
9	Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study. Orphanet Journal of Rare Diseases, 2020, 15, 194.	1.2	12
10	Interprofessional perceptions and emotional impact of multidrug-resistant organisms: A qualitative study. American Journal of Infection Control, 2019, 47, 876-882.	1.1	10
11	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	0.5	10
12	Navigating Communication Challenges in Clinical Practice: A New Approach to Team Education. Critical Care Nurse, 2018, 38, 15-22.	0.5	8
13	De novo truncating <i>NOVA2</i> variants affect alternative splicing and lead to heterogeneous neurodevelopmental phenotypes. Human Mutation, 2022, 43, 1299-1313.	1.1	6
14	Prevalence of Epileptiform Discharges in Healthy Infants. Journal of Child Neurology, 2015, 30, 1409-1413.	0.7	5
15	Evaluation of a Case Management to Support Families With Children Diagnosed With Spinal Muscular Atrophy—Protocol of a Controlled Mixed-Methods Study. Frontiers in Pediatrics, 2021, 9, 614512.	0.9	5
16	Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey. Acta Myologica, 2020, 39, 2-12.	1.5	5
17	Decision-Making Regarding Ventilator Support in Children with SMA Type 1—A Cross-Sectional Survey among Physicians. Neuropediatrics, 2019, 50, 359-366.	0.3	4
18	Interprofessional perceptions of emotional, social, and ethical effects of multidrug-resistant organisms: A qualitative study. PLoS ONE, 2021, 16, e0246820.	1.1	4

THORSTEN LANGER

#	Article	IF	CITATIONS
19	Overcoming language barriers, enhancing collaboration with interpreters – an interprofessional learning intervention (Interpret2Improve). BMC Medical Education, 2022, 22, 170.	1.0	4
20	Medical Students' Development of Ethical Judgment - Exploring the Learners' Perspectives using a mixed methods approach. GMS Journal for Medical Education, 2016, 33, Doc74.	0.1	3
21	Parents' Perspectives on Diagnosis and Decision-Making regarding Ventilator Support in Children with SMA Type 1. Neuropediatrics, 2022, 53, 122-128.	0.3	3
22	Outcomes in Duchenne muscular dystrophy: nature, nurture, culture–or all three?. Developmental Medicine and Child Neurology, 2017, 59, 780-781.	1.1	2
23	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	0.5	2
24	Barriers and Bridges. Academic Pediatrics, 2016, 16, 501-502.	1.0	0
25	Postâ€dural puncture headache—a singleâ€centre analysis in paediatric patients with and without SMA. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 1895-1901.	0.7	0
26	Spasmodic Abdominal Pain and Other Gastrointestinal Symptoms in Pontocerebellar Hypoplasia Type 2. Neuropediatrics, 2021, 52, 495-498.	0.3	0
27	FV 953. Parents' Experiences during the Compassionate Use Program (Nusinersen) for Patients with Spinal Muscular Atrophy Type 1—A Qualitative Interview Study. , 2018, 49, .		0
28	P 900. Decision Making Regarding Ventilator Support in Children with SMA type 1—A Cross-sectional Survey among German Physicians. , 2018, 49, .		0
29	FV 880. Disorders of Coagulation in Duchenne Muscular Dystrophy?—Results of a Registry-Based Online Questionnaire. Neuropediatrics, 2018, 49, .	0.3	0